PURPOSE:Brivaracetam (BRV) is a new anticonvulsant under development. Although BRV is an analog of levetiracetam (LEV), in addition to being an SV2A ligand, it also inhibits sodium channels in a voltage-dependent manner. The cognitive effects of BRV are uncertain. METHODS: A randomized, double-blind, placebo-controlled, four-way cross-over design was employed in 16 healthy volunteers comparing acute dosing (i.e., two doses) of BRV 10 mg, LEV 500 mg, lorazepam (LZP) 2 mg, and placebo. The primary outcome was the summary score from the cognitive neurophysiologic test (CNT), which combines electrophysiologic and performance measures. Secondary outcomes included CNT cognitive and electrophysiologic subscores, traditional neuropsychological measures, and treatment-emergent adverse events (TEAEs). RESULTS: Compared to BRV, LEV, and placebo, LZP adversely affected the CNT summary score and the majority of CNT subscores and neuropsychological measures. In contrast, BRV did not differ from placebo or LEV on any measure. More TEAEs occurred with LZP compared to each of the other treatment conditions. DISCUSSION: The differential pattern of drug effects was consistent across multiple electrophysiologic, cognitive, and subjective measures. The profile of cognitive, subjective, and electrophysiologic effects for BRV was similar to the analog compound LEV and to placebo. The findings suggest that BRV should be tolerated well from a neuropsychological perspective, but additional studies are needed. Wiley Periodicals, Inc.
RCT Entities:
PURPOSE:Brivaracetam (BRV) is a new anticonvulsant under development. Although BRV is an analog of levetiracetam (LEV), in addition to being an SV2A ligand, it also inhibits sodium channels in a voltage-dependent manner. The cognitive effects of BRV are uncertain. METHODS: A randomized, double-blind, placebo-controlled, four-way cross-over design was employed in 16 healthy volunteers comparing acute dosing (i.e., two doses) of BRV 10 mg, LEV 500 mg, lorazepam (LZP) 2 mg, and placebo. The primary outcome was the summary score from the cognitive neurophysiologic test (CNT), which combines electrophysiologic and performance measures. Secondary outcomes included CNT cognitive and electrophysiologic subscores, traditional neuropsychological measures, and treatment-emergent adverse events (TEAEs). RESULTS: Compared to BRV, LEV, and placebo, LZP adversely affected the CNT summary score and the majority of CNT subscores and neuropsychological measures. In contrast, BRV did not differ from placebo or LEV on any measure. More TEAEs occurred with LZP compared to each of the other treatment conditions. DISCUSSION: The differential pattern of drug effects was consistent across multiple electrophysiologic, cognitive, and subjective measures. The profile of cognitive, subjective, and electrophysiologic effects for BRV was similar to the analog compound LEV and to placebo. The findings suggest that BRV should be tolerated well from a neuropsychological perspective, but additional studies are needed. Wiley Periodicals, Inc.
Authors: Marjolein de Groot; Linda Douw; Eefje M Sizoo; Ingeborg Bosma; Femke E Froklage; Jan J Heimans; Tjeerd J Postma; Martin Klein; Jaap C Reijneveld Journal: Neuro Oncol Date: 2012-12-11 Impact factor: 12.300
Authors: Alan Gevins; Linda K McEvoy; Michael E Smith; Cynthia S Chan; Lita Sam-Vargas; Cliff Baum; Aaron B Ilan Journal: Clin Neurophysiol Date: 2011-12-11 Impact factor: 3.708
Authors: Jared F Benge; Richard A Phenis; Abigail Bernett; Daniel Cruz-Laureano; Batool F Kirmani Journal: Front Neurol Date: 2013-12-02 Impact factor: 4.003
Authors: Krista M Lisdahl; Kenneth J Sher; Kevin P Conway; Raul Gonzalez; Sarah W Feldstein Ewing; Sara Jo Nixon; Susan Tapert; Hauke Bartsch; Rita Z Goldstein; Mary Heitzeg Journal: Dev Cogn Neurosci Date: 2018-02-21 Impact factor: 5.811